MTOR and glioma: Mutations or deletions in the PTEN gene commonly lead to activation of the phosphoinositide 3-kinase (PI3K)/protein kinase B (AKT/PKB)/mammalian target of rapamycin (mTOR) signaling network and have previously been reported to be associated with reduced survival of glioma patients [11].